Logo image of RCUS

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD

10.48  +0.39 (+3.87%)

After market: 10.48 0 (0%)

Fundamental Rating

2

RCUS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 549 industry peers in the Biotechnology industry. RCUS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RCUS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCUS has reported negative net income.
RCUS had a negative operating cash flow in the past year.
RCUS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: RCUS reported negative operating cash flow in multiple years.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

The Return On Assets of RCUS (-27.72%) is better than 70.13% of its industry peers.
The Return On Equity of RCUS (-54.28%) is better than 63.21% of its industry peers.
Industry RankSector Rank
ROA -27.72%
ROE -54.28%
ROIC N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

RCUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCUS has more shares outstanding
The number of shares outstanding for RCUS has been increased compared to 5 years ago.
The debt/assets ratio for RCUS is higher compared to a year ago.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RCUS has an Altman-Z score of -0.33. This is a bad value and indicates that RCUS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RCUS (-0.33) is better than 61.38% of its industry peers.
RCUS has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.18, RCUS is not doing good in the industry: 68.31% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -0.33
ROIC/WACCN/A
WACC9.74%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 4.50 indicates that RCUS has no problem at all paying its short term obligations.
The Current ratio of RCUS (4.50) is comparable to the rest of the industry.
RCUS has a Quick Ratio of 4.50. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS has a Quick ratio (4.50) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.5
Quick Ratio 4.5
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for RCUS have decreased by -2.59% in the last year.
RCUS shows a small growth in Revenue. In the last year, the Revenue has grown by 6.07%.
The Revenue has been growing by 76.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-2.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)6.07%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%310.26%

3.2 Future

Based on estimates for the next years, RCUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.45% on average per year.
The Revenue is expected to grow by 25.56% on average over the next years. This is a very strong growth
EPS Next Y-49.84%
EPS Next 2Y-22.47%
EPS Next 3Y-13.19%
EPS Next 5Y9.45%
Revenue Next Year-55.16%
Revenue Next 2Y-24.03%
Revenue Next 3Y-4.63%
Revenue Next 5Y25.56%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RCUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A cheap valuation may be justified as RCUS's earnings are expected to decrease with -13.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.47%
EPS Next 3Y-13.19%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (8/21/2025, 8:04:00 PM)

After market: 10.48 0 (0%)

10.48

+0.39 (+3.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners63.52%
Inst Owner Change1.6%
Ins Owners5.36%
Ins Owner Change4%
Market Cap1.11B
Analysts82.11
Price Target28.75 (174.33%)
Short Float %13.05%
Short Ratio9.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)45.79%
Min EPS beat(2)-8.41%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)29.62%
Min EPS beat(4)-8.41%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)29.65%
EPS beat(12)10
Avg EPS beat(12)23.51%
EPS beat(16)12
Avg EPS beat(16)53.99%
Revenue beat(2)1
Avg Revenue beat(2)186.2%
Min Revenue beat(2)-24.87%
Max Revenue beat(2)397.27%
Revenue beat(4)2
Avg Revenue beat(4)96.47%
Min Revenue beat(4)-24.87%
Max Revenue beat(4)397.27%
Revenue beat(8)6
Avg Revenue beat(8)97.14%
Revenue beat(12)8
Avg Revenue beat(12)71.78%
Revenue beat(16)10
Avg Revenue beat(16)102.09%
PT rev (1m)0%
PT rev (3m)-7.19%
EPS NQ rev (1m)-8.17%
EPS NQ rev (3m)-12.31%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.24%
Revenue NQ rev (1m)-22.9%
Revenue NQ rev (3m)-30.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.24
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 2.02
EV/EBITDA N/A
EPS(TTM)-3.17
EYN/A
EPS(NY)-4.65
Fwd EYN/A
FCF(TTM)-3.23
FCFYN/A
OCF(TTM)-3.2
OCFYN/A
SpS2.47
BVpS5.18
TBVpS5.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.72%
ROE -54.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30%
Cap/Sales 1.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.5
Quick Ratio 4.5
Altman-Z -0.33
F-Score1
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)153.33%
Cap/Depr(5y)249.37%
Cap/Sales(3y)9.4%
Cap/Sales(5y)7.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-49.84%
EPS Next 2Y-22.47%
EPS Next 3Y-13.19%
EPS Next 5Y9.45%
Revenue 1Y (TTM)6.07%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%310.26%
Revenue Next Year-55.16%
Revenue Next 2Y-24.03%
Revenue Next 3Y-4.63%
Revenue Next 5Y25.56%
EBIT growth 1Y-23.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.02%
EBIT Next 3Y-9.26%
EBIT Next 5YN/A
FCF growth 1Y-8.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.89%
OCF growth 3YN/A
OCF growth 5YN/A